

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date  
28 April 2005 (28.04.2005)

PCT

(10) International Publication Number  
**WO 2005/037083 A3**

(51) International Patent Classification<sup>7</sup>: **G01N 33/534, C12Q 1/68**

(21) International Application Number:  
**PCT/US2004/034573**

(22) International Filing Date: 18 October 2004 (18.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/511,832 16 October 2003 (16.10.2003) US

(71) Applicant (for AM, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG only): **BAYER HEALTH-CARE [US/US]; Diagnostic Business Group, 511 Benedict Avenue, Tarrytown, NY 10591-5097 (US).**

(71) Applicant (for all designated States except US): **INSTITUTE OF VIROLOGY [SK/SK]; Slovak Academy of Sciences, Dubravská Cesta 9, 842 46 Bratislava (SK).**

(72) Inventors; and

(75) Inventors/Applicants (for US only): **EBERT, Matthias [DE/DE]; Lentkestrasse 57, 39116 Magdeburg (DE). ROCKEN, Christoph [DE/DE]; Brunnerstrasse 24, 39112 Magdeburg (DE). PASTOREKOVA, Silvia [SK/SK]; Novoveska 18, 841 07 Bratislava (SK). ZAVADA, Jan [CZ/CZ]; Na pekne vyhlidce 1, 162 00 Prague (CZ). PASTOREK, Jaromir [SK/SK]; Novoveska 18, 841 07 Bratislava (SK).**

(74) Agent: **LAUDER, Leona, L.; Suite 1026, 235 Montgomery Street, San Francisco, CA 94104-3008 (US).**

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CR, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:  
**24 November 2005**

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/037083 A3

(54) Title: **MN/CA IX AND CANCER PROGNOSIS**

(57) Abstract: Herein disclosed are methods that are prognostic for neoplastic/preneoplastic disease in a subject vertebrate, wherein said disease is associated with a tissue that normally expresses MN, but which MN expression is lost or diminished upon carcinogenesis. Exemplary of the types of preneoplastic/neoplastic diseases subject to the prognostic methods of this invention are those of gastric mucosa, gallbladder, biliary ducts, and ductal cells of duodenal glands. An exemplary prognostic method comprises comparing the level of MN gene expression product in a tissue sample from the affected subject, with the average MN gene expression product level found in analogous preneoplastic/neoplastic tissue samples; an above average MN gene expression product level indicates poorer prognosis for the subject. MN gene expression products useful in the prognostic methods include MN protein, MN polypeptide, and/or MN nucleic acids.